UMMY20031/ UMCC 2018.056/ Brea Lipe
Basic Study Information
Purpose:Location: University of Rochester
This phase 2 trial will test whether the combination of DaraRd (daratumumab + lenalidomide
+ dexamethasone) as induction therapy, followed by DRVd (daratumumab + lenalidomide
+ bortezomib + dexamethasone) consolidation therapy, if needed, will result in more
patients achieving minimal residual disease (MRD)-negative status, relative to the
standard of care. Consolidation therapy will be administered only to those patients
with MRD-positive status after induction therapy.
This is a study based on adaptive design for decision making of treatment options.
Duration of therapy (daratumumab cycles) will depend on individual approach, response,
evidence of disease progression and tolerance.
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search